Sonnet BioTherapeutics Approves Merger with Hyperliquid and Rorschach

 On December 2, 2025, Sonnet BioTherapeutics Holdings announced that its stockholders approved a proposed business combination with Hyperliquid Strategies Inc and Rorschach I LLC. This strategic move is expected to enhance Sonnet’s market positioning by potentially expanding its capabilities and offerings in the biotechnology sector.

https://www.tipranks.com/news/company-announcements/sonnet-biotherapeutics-approves-merger-with-hyperliquid-and-rorschach